---
document_datetime: 2025-12-02 06:31:39
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/topotecan-teva.html
document_name: topotecan-teva.html
version: success
processing_time: 0.1066533
conversion_datetime: 2025-12-25 07:03:28.621296
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Topotecan Teva

[RSS](/en/individual-human-medicine.xml/66960)

##### Withdrawn

This medicine's authorisation has been withdrawn

topotecan Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European Public Assessment Report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the Scientific Discussion (also part of the EPAR).

Expand section

Collapse section

## What is Topotecan Teva?

Topotecan Teva is a concentrate that is made up into a solution for infusion (drip into a vein). It contains the active substance topotecan.

Topotecan Teva is a 'generic medicine'. This means that Topotecan Teva is similar to a 'reference medicine' already authorised in the European Union (EU) called Hycamtin.

## What is Topotecan Teva used for?

Topotecan Teva is an anticancer medicine. It is used on its own to treat patients with:

- metastatic cancer of the ovary (when the cancer has spread to other parts of the body). It is used after at least one other treatment has failed;
- small cell lung cancer, when the cancer has relapsed (come back). It is used when giving the original treatment again is not recommended.

It is also used together with cisplatin (another anticancer medicine) to treat women with cervical cancer (cancer of the cervix), when the cancer has come back after radiotherapy, or when the disease is at an advanced stage (stage IVB: the cancer has spread beyond the cervix).

The medicine can only be obtained with a prescription.

## How is Topotecan Teva used?

Treatment with Topotecan Teva should only be given under the supervision of a doctor experienced in the use of chemotherapy. Infusions should be carried out in a specialised cancer ward. The patient's blood levels of white blood cells, platelets and haemoglobin should be checked before treatment, to ensure that they are above set minimum levels. The doses may need to be adjusted or other medicines given to the patients, when the level of white blood cells remains particularly low.

The dose of Topotecan Teva to be used depends on the type of cancer that it is being used to treat and the patient's weight and height. Topotecan Teva is given as an infusion lasting 30 minutes every day for five days with a three-week interval between the start of each course. Treatment may continue until the disease gets worse.

When used with cisplatin in cervical cancer, Topotecan Teva is given on days 1, 2 and 3 (with cisplatin given on day 1). This is repeated every 21 days for six courses or until the disease gets worse.

For full details, see the Summary of Product Characteristics (also part of the EPAR).

## How does Topotecan Teva work?

The active substance in Topotecan Teva, topotecan, is an anticancer medicine that belongs to the group 'topoisomerase inhibitors'. It blocks an enzyme called topoisomerase I, which is involved in the division of DNA. When the enzyme is blocked, the DNA strands break. This prevents the cancer cells from dividing and they eventually die. Topotecan Teva also affects non-cancer cells, which causes side effects.

## How has Topotecan Teva been studied?

Because Topotecan Teva is a generic medicine, the company has provided data from the published literature on topotecan. No additional studies were needed as Topotecan Teva is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Hycamtin.

## What are the benefit and risk of Topotecan Teva?

Because Topotecan Teva is a generic medicine, its benefit and risk are taken as being the same as those of the reference medicine.

## Why has Topotecan Teva been approved?

The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Topotecan Teva has been shown to be comparable to Hycamtin. Therefore, the CHMP's view was that, as for Hycamtin, the benefit outweighs the identified risk. The Committee recommended that Topotecan Teva be given marketing authorisation.

## Other information about Topotecan Teva

The European Commission granted a marketing authorisation valid throughout the EU for Topotecan Teva to Teva Pharma B.V. on 21 September 2009.

Topotecan Teva : EPAR - Summary for the public

English (EN) (43.45 KB - PDF)

**First published:** 06/10/2009

**Last updated:** 06/10/2009

[View](/en/documents/overview/topotecan-teva-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-770)

български (BG) (166.34 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/bg/documents/overview/topotecan-teva-epar-summary-public_bg.pdf)

español (ES) (45.28 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/es/documents/overview/topotecan-teva-epar-summary-public_es.pdf)

čeština (CS) (155.31 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/cs/documents/overview/topotecan-teva-epar-summary-public_cs.pdf)

dansk (DA) (44.45 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/da/documents/overview/topotecan-teva-epar-summary-public_da.pdf)

Deutsch (DE) (45.24 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/de/documents/overview/topotecan-teva-epar-summary-public_de.pdf)

eesti keel (ET) (44.07 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/et/documents/overview/topotecan-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (176.17 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/el/documents/overview/topotecan-teva-epar-summary-public_el.pdf)

français (FR) (45.51 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/fr/documents/overview/topotecan-teva-epar-summary-public_fr.pdf)

italiano (IT) (44.94 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/it/documents/overview/topotecan-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (176.12 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/lv/documents/overview/topotecan-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (152.38 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/lt/documents/overview/topotecan-teva-epar-summary-public_lt.pdf)

magyar (HU) (148.85 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/hu/documents/overview/topotecan-teva-epar-summary-public_hu.pdf)

Malti (MT) (167.79 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/mt/documents/overview/topotecan-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (44.53 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/nl/documents/overview/topotecan-teva-epar-summary-public_nl.pdf)

polski (PL) (164 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/pl/documents/overview/topotecan-teva-epar-summary-public_pl.pdf)

português (PT) (45.15 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/pt/documents/overview/topotecan-teva-epar-summary-public_pt.pdf)

română (RO) (148.59 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/ro/documents/overview/topotecan-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (151.83 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/sk/documents/overview/topotecan-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (114.63 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/sl/documents/overview/topotecan-teva-epar-summary-public_sl.pdf)

Suomi (FI) (44.39 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/fi/documents/overview/topotecan-teva-epar-summary-public_fi.pdf)

svenska (SV) (44.26 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/sv/documents/overview/topotecan-teva-epar-summary-public_sv.pdf)

## Product information

Topotecan Teva : EPAR - Product Information

English (EN) (271.06 KB - PDF)

**First published:** 06/10/2009

**Last updated:** 13/07/2018

[View](/en/documents/product-information/topotecan-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-60)

български (BG) (384.13 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/bg/documents/product-information/topotecan-teva-epar-product-information_bg.pdf)

español (ES) (273.21 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/es/documents/product-information/topotecan-teva-epar-product-information_es.pdf)

čeština (CS) (353.5 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/cs/documents/product-information/topotecan-teva-epar-product-information_cs.pdf)

dansk (DA) (277.78 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/da/documents/product-information/topotecan-teva-epar-product-information_da.pdf)

Deutsch (DE) (291.07 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/de/documents/product-information/topotecan-teva-epar-product-information_de.pdf)

eesti keel (ET) (261.97 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/et/documents/product-information/topotecan-teva-epar-product-information_et.pdf)

ελληνικά (EL) (391.85 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/el/documents/product-information/topotecan-teva-epar-product-information_el.pdf)

français (FR) (289.2 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/fr/documents/product-information/topotecan-teva-epar-product-information_fr.pdf)

hrvatski (HR) (352.33 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/hr/documents/product-information/topotecan-teva-epar-product-information_hr.pdf)

íslenska (IS) (283.22 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/is/documents/product-information/topotecan-teva-epar-product-information_is.pdf)

italiano (IT) (298.84 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/it/documents/product-information/topotecan-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (363.02 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/lv/documents/product-information/topotecan-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (338.87 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/lt/documents/product-information/topotecan-teva-epar-product-information_lt.pdf)

magyar (HU) (351.65 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/hu/documents/product-information/topotecan-teva-epar-product-information_hu.pdf)

Malti (MT) (394.75 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/mt/documents/product-information/topotecan-teva-epar-product-information_mt.pdf)

Nederlands (NL) (278.6 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/nl/documents/product-information/topotecan-teva-epar-product-information_nl.pdf)

norsk (NO) (268.3 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/no/documents/product-information/topotecan-teva-epar-product-information_no.pdf)

polski (PL) (362.54 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/pl/documents/product-information/topotecan-teva-epar-product-information_pl.pdf)

português (PT) (282.64 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/pt/documents/product-information/topotecan-teva-epar-product-information_pt.pdf)

română (RO) (384.72 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/ro/documents/product-information/topotecan-teva-epar-product-information_ro.pdf)

slovenčina (SK) (373.64 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/sk/documents/product-information/topotecan-teva-epar-product-information_sk.pdf)

slovenščina (SL) (348.46 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/sl/documents/product-information/topotecan-teva-epar-product-information_sl.pdf)

Suomi (FI) (278.91 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/fi/documents/product-information/topotecan-teva-epar-product-information_fi.pdf)

svenska (SV) (277.87 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

13/07/2018

[View](/sv/documents/product-information/topotecan-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0014 22/06/2018

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Topotecan Teva : EPAR - All Authorised presentations

English (EN) (12.04 KB - PDF)

**First published:** 06/10/2009

**Last updated:** 06/10/2009

[View](/en/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-964)

български (BG) (78.09 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/bg/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (12.61 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/es/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (78.82 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/cs/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (12.6 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/da/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (12.85 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/de/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (12.49 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/et/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (76.91 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/el/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (12.5 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/fr/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (12.23 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/it/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (78.14 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/lv/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (77.42 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/lt/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (43.15 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/hu/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (79.16 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/mt/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (12.12 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/nl/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_nl.pdf)

polski (PL) (82.12 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/pl/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (12.63 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/pt/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (75.19 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/ro/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (42.8 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/sk/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (12.14 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/sl/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (12.3 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/fi/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (12.67 KB - PDF)

**First published:**

06/10/2009

**Last updated:**

06/10/2009

[View](/sv/documents/all-authorised-presentations/topotecan-teva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Topotecan Teva Active substance topotecan International non-proprietary name (INN) or common name topotecan Therapeutic area (MeSH)

- Ovarian Neoplasms
- Uterine Cervical Neoplasms
- Small Cell Lung Carcinoma

Anatomical therapeutic chemical (ATC) code L01CE01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Topotecan monotherapy is indicated for the treatment of:

- patients with metastatic carcinoma of the ovary after failure of first line or subsequent therapy;
- patients with relapsed small cell lung cancer [SCLC] for whom re-treatment with the first-line regimen is not considered appropriate.

Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.

## Authorisation details

EMA product number EMEA/H/C/001071

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva B.V.

Swensweg 5

Marketing authorisation issued 21/09/2009 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Topotecan Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (88.06 KB - PDF)

**First published:** 12/02/2010

**Last updated:** 13/07/2018

[View](/en/documents/procedural-steps-after/topotecan-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Topotecan Teva : EPAR - Public assessment report

English (EN) (113.18 KB - PDF)

**First published:** 06/10/2009

**Last updated:** 06/10/2009

[View](/en/documents/assessment-report/topotecan-teva-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use, summary of positive opinion for Topotecan Teva

Reference Number: EMEA/CHMP/383983/2009

English (EN) (32.98 KB - PDF)

**First published:** 25/06/2009

**Last updated:** 25/06/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-topotecan-teva_en.pdf)

**This page was last updated on** 13/07/2018

## Share this page

[Back to top](#main-content)